Loading…
Aurobindo Pharma (AUROPHARMA)₹1,855+2.84%Pharmaceuticals
At the end of the Jun 2026 quarter, Aurobindo Pharma's shareholders were: promoters 51.87%, FIIs 16.40%, DIIs 25.04%, government 0.05%, public 6.64%. Promoter holding is up 0.06 percentage points from 51.81% a quarter earlier. FII holding is up 2.00 percentage points from 14.40% a year earlier. 13.81% of promoter shares were pledged. It had 2,39,103 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 51.83% | 51.83% | 51.83% | 51.79% | 51.81% | 51.81% | 51.81% | 51.81% | 51.81% | 51.81% | 51.81% | 51.87% |
| FIIs | 22.47% | 20.74% | 18.03% | 16.75% | 16.61% | 16.31% | 15.35% | 14.40% | 14.23% | 13.97% | 15.26% | 16.40% |
| DIIs | 18.28% | 20.59% | 23.27% | 24.76% | 25.13% | 25.20% | 26.22% | 26.92% | 27.59% | 27.65% | 25.81% | 25.04% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% | 0.05% | 0.05% |
| Public | 7.42% | 6.84% | 6.87% | 6.70% | 6.45% | 6.68% | 6.62% | 6.87% | 6.37% | 6.54% | 7.07% | 6.64% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 13.81% |
| Number of shareholders | 2,59,671 | 2,41,975 | 2,44,606 | 2,38,652 | 2,48,519 | 2,57,995 | 2,69,357 | 2,72,243 | 2,47,693 | 2,36,889 | 2,41,329 | 2,39,103 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding) | Promoter | 33.55% | +0.04 |
| Quant Mutual Fund | DII | 4.98% | New |
| Kambam Nithyananda Reddy | Promoter | 4.36% | 0.00 |
| Sbi Large & Midcap Fund | DII | 3.60% | New |
| Kirthi Reddy Kambam | Promoter | 3.45% | +0.01 |
| Hdfc Mutual Fund | DII | 3.19% | New |
| Venkata Ramprasad Reddy Penaka | Promoter | 3.10% | 0.00 |
| Life Insurance Corporation Of India | DII | 2.97% | +0.01 |
| Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.Ltd. (Jointly Holding) | Promoter | 2.88% | +0.01 |
| Nps Trust - A/C Sbi Pension Fund Scheme - Nps Tier | DII | 2.76% | New |
| M Sivakumaran | Promoter | 2.46% | +0.01 |
| Kambam Spoorthi | Promoter | 1.19% | +0.01 |
| Kottamanchi Rajeswari | Promoter | 0.31% | 0.00 |
| M Sumanth Kumar Reddy | Promoter | 0.27% | 0.00 |
| Trident Chemphar Limited | Promoter | 0.13% | 0.00 |
| Axis Clinicals Limited | Promoter | 0.11% | 0.00 |
| Prasada Reddy Kambham | Promoter | 0.05% | 0.00 |
| Suneela Rani Penaka | Promoter | 0.02% | 0.00 |
| Quant Mutual Fund - Quant Arbitrage Fund | DII | Exited | — |
| Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advant | DII | Exited | — |
| Nps Trust- A/C Icici Prudential Pension Fund Schem | DII | Exited | — |
| Icici Prudential India Opportunities Fund | DII | Exited | — |
| Sbi Balanced Advantage Fund | DII | Exited | — |
Promoters held 51.87% of Aurobindo Pharma at the end of the Jun 2026 quarter, up 0.06 percentage points from 51.81% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 16.40% (up 1.14 percentage points from 15.26% a quarter earlier) and domestic institutions (DIIs) held 25.04% (down 0.77 percentage points from 25.81% a quarter earlier).
Yes. 13.81% of promoter shares were pledged at the end of the Jun 2026 quarter.
Aurobindo Pharma had 2,39,103 shareholders at the end of the Jun 2026 quarter, against 2,72,243 a year earlier.
Quant Mutual Fund (DII) held 4.98% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.